MHRA refreshes GCP inspection guidance as UK and US tighten early-trial oversight

What happened

On 6 November 2026 the MHRA updated its guidance page on good clinical practice (GCP) inspections for clinical trials of medicines. According to the record, the page sets out risk-based and triggered inspections, dossier requests and the inspection process, and names ICH E6(R3) as the reference standard.

The record does not say what changed against the previous version of the page, so any claim about new inspection powers or shifted expectations would be speculation. What can be said is that the MHRA has put its inspection model, the document requests that precede inspections and the sequence of an inspection in one place, anchored to the revised international GCP guideline.

Why the reference standard matters

Naming ICH E6(R3) as the yardstick tells sponsors, CROs and investigator sites which version of GCP inspectors will measure them against. Teams still running procedures, SOPs and training built around the earlier GCP text should compare them with E6(R3) now, rather than discovering gaps in the middle of an inspection.

The two inspection routes also call for different preparation. A risk-based inspection is, in general terms, selected by the regulator on the basis of a risk assessment of the sponsor, site or trial. A triggered inspection follows a specific concern. Dossier requests are a practical early signal. Organisations that can only assemble trial master file material, oversight records and quality documentation slowly will feel the pressure first.

A wider UK pattern: non-clinical data and test facilities

Two days earlier, on 4 November, the MHRA published guidance on how it will assess non-clinical data generated outside the OECD Mutual Acceptance of Data (MAD) system. Per the record, it explains when UK trial applications relying on such safety data may be considered, describes enhanced assessment in limited circumstances, and mentions a programme of test facility inspections.

Read together, the two items show the MHRA looking at data integrity and compliance at both ends of development: the laboratories that generate the safety package supporting a trial application, and the conduct of the trial itself. The records do not link the two documents formally, and we should not assume a single policy. But sponsors with UK applications that depend on non-OECD MAD data should expect closer scrutiny of that package and plan their evidence accordingly.

The US is working on speed, with oversight intact

Across the Atlantic, FDA's CBER closed applications to its Expedited IND pilot after more than 100 submissions, with selections due by 18 December. The pilot sits under HHS Operation TrialBlazer and will test whether outside expert institutions and rolling review can speed first-in-human trials without lowering safety or oversight standards.

CBER also detailed the pilot's structure. Sponsors will submit discipline-specific components during pre-IND development, and a QRI will vet each one before the 30-day review begins. Most activity therefore falls before the formal IND. The records do not say how many applicants will be chosen or what the pilot's results will be.

The contrast is useful. The FDA pilot is about moving review earlier and making it incremental. The MHRA material is about how it verifies data quality and trial conduct. Neither replaces the other, and faster entry into the clinic does not reduce the expectation that trials are run to a defensible GCP standard.

Who is affected and what to watch

The MHRA page is most relevant to UK-facing sponsors, CROs, and sites, including those running global programmes with UK participants. Quality and clinical operations leads are the main audience, since inspection readiness spans both.

Sponsor disclosures show how regulator interaction is becoming part of development planning. Xencor said it plans to meet the FDA in the first half of 2027 on a possible accelerated approval route for XmAb819. Arvinas reported that ARV-6723 is in a Phase 1/2 solid tumour trial and that EU and UK filings are planned for ARV-102 in PSP. These records say nothing about inspections, and we draw no inference about either company's compliance. They are simply examples of programmes moving into regulatory interactions where data and trial conduct will be examined.

Open questions remain. The MHRA record does not specify inspection volumes, timelines for dossier responses or any transition arrangements for E6(R3). The FDA pilot's selected participants are not yet known. Teams should read the full MHRA page directly and track the 18 December selection date.